Q-omics provides the consensus-scored LRCH1 profile across patient tissues and cancer cell-line models. LRCH1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LRCH1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LRCH1 protein abundance shows 31,947 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where LRCH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRCH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRCH1 survival associations across molecular data types. LRCH1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRCH1 RNA expression–survival associations across cancer types. High LRCH1 expression shows unfavorable associations in BLCA, CESC and LGG, but favorable associations in KIRC, BRCA and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LRCH1 RNA expression.
This table summarizes LRCH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LRCH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRCH1 shows lower tumor expression in KICH, UCEC, BLCA and LUAD and higher tumor expression in HNSC and COAD. The HNSC box plot shows higher LRCH1 RNA expression in tumor versus normal tissue (log2 FC = +0.830, t-test p < 0.001).
This table shows molecular features associated with LRCH1 in patient tissues and cancer cell lines. In patient samples, LRCH1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRCH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
